Loading
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$9.60
−$0.26 · -2.64%
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Previous close
$9.60
−$0.26 · -2.64%
Regular session · ET · Market data may be delayed.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Day range
Current $9.60
52-week range
Current $9.60
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
52
Mixed
Risk
22
Moderate Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Day range
Current $9.60
52-week range
Current $9.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (GBP) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.03B GBP | 11.23B GBP | 11.3B GBP | 10.86B GBP | 9.55B GBP |
| Cost of goods sold | 3.83B GBP | 4.29B GBP | 4.34B GBP | 4.28B GBP | 3.6B GBP |
| Gross profit | 6.99B GBP | 6.95B GBP | 6.96B GBP | 6.58B GBP | 5.95B GBP |
| Research and development | 308.1M GBP | 298M GBP | 311M GBP | 300M GBP | 257M GBP |
| Selling, general, and administrative | 4.36B GBP | 4.33B GBP | 4.29B GBP | 4.04B GBP | 3.79B GBP |
| Operating expenses | 4.43B GBP | 4.74B GBP | 4.97B GBP | 4.75B GBP | 4.31B GBP |
| Interest income | 76.29M GBP | 55M GBP | 14M GBP | 68.98M GBP | 13M GBP |
| Interest expense | 332.55M GBP | 394M GBP | 414M GBP | 347.36M GBP | 16M GBP |
| Depreciation and amortization | 352.11M GBP | 196M GBP | 309M GBP | 287M GBP | 268M GBP |
| Operating income | 2.41B GBP | 2.21B GBP | 2B GBP | 1.83B GBP | 1.64B GBP |
| Net income | 1.63B GBP | 1.44B GBP | 1.05B GBP | 1.06B GBP | 1.39B GBP |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.20
6.25% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Cash distributions grouped by calendar year; partial years are marked.
$0.1764
2025 complete year+70.1% since 2023
2026 partial: $0.1975
$0.1037
2,023
$0.1578
2,024
$0.1764
2,025
$0.1975
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 14, 2026 | $0.0642Semi-Annual | Aug 14, 2026 | Sep 17, 2026 |
Dividend | Apr 10, 2026 | $0.1333Semi-Annual | Apr 10, 2026 | May 14, 2026 |
Dividend | Aug 15, 2025 | $0.0598Semi-Annual | Aug 15, 2025 | Sep 18, 2025 |
Dividend | Apr 25, 2025 | $0.1166Semi-Annual | Apr 25, 2025 | Jun 5, 2025 |
Dividend | Aug 16, 2024 | $0.0514Semi-Annual | Aug 16, 2024 | Sep 19, 2024 |
Dividend | Mar 14, 2024 | $0.1064Semi-Annual | Mar 15, 2024 | May 16, 2024 |
Ex-dividend Aug 14, 2026
$0.0642
Semi-Annual
Record Aug 14, 2026 · Payment Sep 17, 2026
Ex-dividend Apr 10, 2026
$0.1333
Semi-Annual
Record Apr 10, 2026 · Payment May 14, 2026
Ex-dividend Aug 15, 2025
$0.0598
Semi-Annual
Record Aug 15, 2025 · Payment Sep 18, 2025
Ex-dividend Apr 25, 2025
$0.1166
Semi-Annual
Record Apr 25, 2025 · Payment Jun 5, 2025
Ex-dividend Aug 16, 2024
$0.0514
Semi-Annual
Record Aug 16, 2024 · Payment Sep 19, 2024
Ex-dividend Mar 14, 2024
$0.1064
Semi-Annual
Record Mar 15, 2024 · Payment May 16, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Developed World ex-US ETFSPDW53.71M0.13%42.37B USD0.03%$52.31+0.40%
VanEck Pharmaceutical ETFPPH32.84M3.09%1.05B USD0.36%$114.21-1.35%
Avantis International Equity ETFAVDE8.97M0.05%19.34B USD0.23%$94.51+0.01%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH6.11M0.58%933.15M USD0.13%$29.0078-1.29%
GMO International Quality ETFQLTI4.81M1.60%298M USD0.60%$27.56-0.22%
Franklin ClearBridge Enhanced Income ETFYLDE4.07M2.33%173.78M USD0.48%$56.9946-0.54%
Scharf Global Opportunity ETFGKAT3.66M2.16%132M USD0.59%$45.9124+0.07%
John Hancock Investments - Multifactor Developed International ETFJHMD3.61M0.37%973.21M USD0.39%$46.58+0.22%State Street SPDR Portfolio Developed World ex-US ETFSPDWVanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEPortfolio Building Block World Pharma and Biotech Index ETFPBPHGMO International Quality ETFQLTIFranklin ClearBridge Enhanced Income ETFYLDEScharf Global Opportunity ETFGKATJohn Hancock Investments - Multifactor Developed International ETFJHMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
